Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

Incidence and risk factors of ocular hypertension following ıntravitreal dexamethasone implantation: the role of baseline intraocular pressure. (PubMed, Int Ophthalmol) - "Intravitreal Ozurdex implantation is associated with a significant increase in IOP, necessitating close monitoring. Higher baseline IOP and male gender were identified as major risk factors. While the majority of cases were successfully managed with topical therapy, a small proportion required surgical intervention. Further research is warranted to improve risk stratification and optimize management strategies."

Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Dexamethasone intravitreal implant combines with VEGFR fusion protein versus VEGFR fusion protein alone for Diabetic Macular Edema: a multicentre, randomized, open-label clinical trial (ChiCTR) - P2 | N=98 | Completed | Sponsor: The Second Affiliated Hospital of Air Force Military Medical University,Chinese People’s Liberation Army; The Second Affiliated Hospital of Air Forc

New P2 trial • Diabetic Macular Edema • Ophthalmology

Delayed-Onset Endophthalmitis After Intravitreal Dexamethasone Implantation. (PubMed, J Vitreoretin Dis) - "Purpose: To present a series of cases of acute endophthalmitis after intravitreal (IVT) sustained-release dexamethasone implantation (Ozurdex) with an unusually delayed onset... Delayed-onset acute endophthalmitis after dexamethasone implantation represents a clinical challenge, potentially occurring up to weeks after the injection. Sustained suspicion for endophthalmitis is warranted given that cases may present beyond what is typical for postinjection endophthalmitis."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology

Predictive Value of Optical Coherence Tomography Biomarkers in Patients with Persistent Diabetic Macular Edema Undergoing Cataract Surgery Combined with a Dexamethasone Intravitreal Implant. (PubMed, Bioengineering (Basel)) - " The administration of DEX-I for DME refractory to anti-VEGF treatment in patients undergoing cataract surgery promoted functional improvements persisting longer than the anatomical ones. Patients presenting with DRIL, disrupted EZ, and higher CST at baseline may be better candidates for the combination of DEX-I and cataract surgery."

Biomarker • Journal • Cataract • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. (PubMed, Int J Ophthalmol) - "Intravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up."

Journal • Monotherapy • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

YAG Laser-Assisted Fragmentation of Dexamethasone Implants in the Anterior Chamber. (PubMed, Retina) - "Spontaneous migration of the dexamethasone intravitreal implant into the anterior chamber can occur in patients with aphakia, prior pars plana vitrectomy, or compromised capsular support. Timely intervention using Nd:yag laser can effectively fragment the dexamethasone implant, mitigating the risk of corneal endothelial damage and preserving visual function. In this cohort Nd:yag laser appeared a safe and effective treatment option for managing anterior chamber migration of the dexamethasone intravitreal implant, avoiding the need for more invasive surgical techniques or temporary non-invasive techniques."

Journal • Cataract • Macular Edema • Ophthalmology

Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis. (PubMed, J Ophthalmic Inflamm Infect) - "SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis."

Journal • Cardiovascular • Glaucoma • Immunology • Infectious Disease • Inflammatory Arthritis • Ocular Infections • Ocular Inflammation • Ophthalmology • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Scleritis • Vasculitis

Anterior chamber migration of an Ozurdex implant with Carlevale intraocular lens (PubMed, Ophthalmologie) - No abstract available

Journal

Subconjunctival dexamethasone implant (Ozurdex) in the management of refractory Non-Infectious anterior scleritis (J Ophthalmic Inflamm Infect) - "In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI."

Retrospective data • Eosinophilic Granulomatosis With Polyangiitis • Ophthalmology • Rheumatoid Arthritis

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (clinicaltrials.gov) - P1/2 | N=37 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Mar 2025

Trial completion • Trial completion date • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Blinded by Prostatic Adenocarcinoma - A Case of Cancer Associated Retinopathy with Multimodal Imaging. (PubMed, Ocul Immunol Inflamm) - "Inspite of intravenous methylprednisolone followed by oral steroids and therapeutic trial of antitubercular therapy, progression in the right eye threatening the fovea was noted in 9 days. Intravitreal ozurdex was given (OU) following which there was no progression. He also received mycophenolate mofetil 2 gm/day and hormonal therapy for the adenocarcinoma of the prostate...The autofluorescence and OCT show characteristic outer retinal involvement at the level of the RPE and photoreceptors. Intravitreal dexamethasone implant is a good option to prevent further vision loss."

Journal • Non Small Cell Lung Cancer • Ocular Melanoma • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Retinal Disorders

12-C-0107: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov) - P2 | N=55 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2028 ➔ Feb 2025

Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Smoldering Multiple Myeloma

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. (PubMed, J Clin Med) - " This retrospective study included patients from LMU University Hospital who were switched to Faricimab due to an inadequate response or adverse events related to prior intravitreal therapy (Ranibizumab, Aflibercept, or OzurdexTM). Given the small sample size and retrospective design, these findings should be interpreted as exploratory and hypothesis-generating. Further studies are needed to evaluate long-term efficacy and optimal treatment regimens."

Journal • Real-world evidence • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Effect of dexamethasone intravitreal implant on macular edema in vitrectomy eyes (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: The second hospital of Dalian Medical University; The second hospital of Dalian Medical University

New trial • Diabetic Macular Edema • Macular Edema • Ophthalmology

Switch to faricimab in various retinal diseases: real-world data (ARVO 2025) - "Previous treatments included bevacizumab, ranibizumab, aflibercept 2mg, brolucizumab, triamcinolone, and Ozurdex. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Outcomes of Diabetic Macular Edema During Pregnancy and the Postpartum (ARVO 2025) - "Nine eyes with pre-pregnancy DME received treatments including bevacizumab (1), Ozurdex (6), and Ranibizumab (2). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Cataract • Diabetic Macular Edema • Ophthalmology

Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review. (PubMed, Diagnostics (Basel)) - "Studies evaluating topical NSAIDs, periocular steroids, intravitreal triamcinolone acetonide (TCA), dexamethasone implants (Ozurdex), and intravitreal bevacizumab were included... Topical NSAIDs, particularly ketorolac and diclofenac, showed effectiveness in acute CMO, while their efficacy in chronic cases was variable... Topical NSAIDs, often combined with periocular steroids, serve as first-line therapy, with periocular steroids offering additional efficacy in resistant cases. Further research is needed to establish optimal treatment algorithms and improve outcomes for patients with post-operative CMO."

Journal • Review • Cataract • Macular Edema • Ophthalmology

Ethnicity & Intraocular pressure (IOP) spike rates of Diabetic Macular Edema (DME) patients: IOP outcomes after 30,172 intravitreal injections from 2014 - 2024 from a single hospital in the United Kingdom (UK) (ARVO 2025) - "IVI agents analysed include Eylea 2 mg (Aflibercept), Vabysmo (Faricimab), Avastin (Bevaziumab), Ongavia (Ranibizumab biosimilar), Lucentis (Ranibizumab), Ozurdex (Dexamethasone implant), Iluvien (Fluocinolone). Insights in the IOP spike rates of various treatment agents used for DME in diverse ethnic populations can inform clinicians on the optimal treatment agent of choice for DME patients. Additionally, it enables tailored risk stratification and patient counselling for shared decision-making."

Clinical • Diabetic Macular Edema • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis

Ethnicity & Intraocular pressure (IOP) spike rates of Central Retinal Vein Occlusion (CRVO) & Branch Retinal Vein Occlusion (BRVO) patients: IOP outcomes after 26,471 intravitreal injections from 2014-2024 from a single hospital in the United Kingdom (UK) (ARVO 2025) - "IVIs included were: Eylea 2mg (Aflibercept), Ongavia (Ranibizumab biosimilar), Avastin (Bevacizumab), Vabysmo (Faricimab), Lucentis 0.5mg (Ranibuzumab) & Ozurdex (Dexamethasone) implant. Ethnic differences may also influence IVI IOP spikes. Understanding the IOP spike rates in different IVIs used in CRVO & BRVO across different ethnicities may help clinicians in the management of their patients and inform choice of IVI for a more favourable safety profile."

Clinical • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Efficacy of Intravitreal Dexamethasone Implant (Ozurdex®) in Naïve and Refractory Patients with Different Morphological Subtypes of Diabetic Macular Edema. (PubMed, Medicina (Kaunas)) - "All subjects received a single injection of the dexamethasone implant. The presence of SRD was associated with more favorable anatomical results, while CME was associated with better visual acuity. Dexamethasone provided superior results in previously treated patients."

Clinical • Journal • Retrospective data • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Post-operative Fibrinoid Syndrome in Eyes Receiving Dexamethasone Implant (ARVO 2025) - "Purpose Intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, CA, USA) and pars-plana vitrectomy (PPV) are both used in the treatment of diabetic retinopathy...Our results showed an incidence of POFS was 3.8%, which is lower than that of previously published data Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Travel – associated emissions of intravitreal injections (ARVO 2025) - "Medication included anti-VEGF agents (94%), dexamethasone intravitreal implants (4%), triamcinolone (0.3%), and ganciclovir (2%). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Diabetic Macular Edema • Ophthalmology • Wet Age-related Macular Degeneration

Inflammation Targeted Treatment of Diabetic Macular Edema using Optical Coherence Tomography (OCT) Morphology (ARVO 2025) - "The clinical importance of the study is in recognizing eyes with a unique OCT morphology that suggests they may respond well to dexamethasone intravitreal implants. Administering this treatment before or at the start of anti-VEGF treatments, could effectively resolve DME more quickly while reducing both the treatment burden on patients and the overall societal costs."

Diabetic Macular Edema • Ophthalmology

Post-hoc Analysis of Association of Baseline Characteristics and IOP Rise with Dexamethasone Implant in Phase 3 Studies (ARVO 2025) - P3 | "Purpose Dexamethasone intravitreal (IVI) implant 0.7 mg (DEX-I, OZURDEX®), an approved treatment for diabetic macular edema (DME), is associated with increased intraocular pressure (IOP) in ~30% of treated patients...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

P3 data • Retrospective data • Diabetic Macular Edema • Glaucoma • Ophthalmology

Aqueous Humor Cytokines and Imaging Features in Diabetic Macular Edema Treated with Intraocular Steroids with and without Supplemental Anti-Vascular Endothelial Growth Factor Therapy (ARVO 2025) - "Total VEGF concentrations were elevated in the patients that only required ozurdex, but VEGF R2 (Median 621pg/mL DEX, 725pg/mL DEX+IAI) and VEGF R3 (Median 374pg/mL DEX, 419pg/mL DEX+IAI) were higher in the patients the DEX group, while TGFα, in contrast, was lower...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Macular Edema • Ocular Inflammation • Ophthalmology • ANGPT1 • FLT4 • IL10 • IL4 • TGFA